Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1392&sort=award_amount
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=award_amount", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=award_amount", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=award_amount", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=award_amount" }, "data": [ { "type": "Grant", "id": "9232", "attributes": { "award_id": "75N93020C00054-P00001-9999-1", "title": "DEVELOPMENT OF THERAPEUTIC PRODUCTS FOR COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-09-01", "end_date": "2025-08-31", "award_amount": 8955992, "principal_investigator": { "id": 24970, "first_name": "JEFFREY", "last_name": "GLENN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "To support the advanced development of a promising candidate therapeutic for NIAID Category A, B, and C Priority Pathogens or emerging infectious diseases. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development pathway, and include preclinical and IND enabling development activities, chemistry optimization/development, GMP manufacturing, and clinical safety and efficacy assessment.", "keywords": [ "Advanced Development", "COVID-19", "COVID-19 therapeutics", "Categories", "Chemistry", "Clinical", "Development", "Emerging Communicable Diseases", "National Institute of Allergy and Infectious Disease", "Pathway interactions", "efficacy evaluation", "pre-clinical", "priority pathogen", "product development", "research and development", "safety assessment", "therapeutic candidate", "therapeutic development" ], "approved": true } }, { "type": "Grant", "id": "5336", "attributes": { "award_id": "0802876", "title": "The Sloan Digital Sky Survey --Phase III", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Mathematical and Physical Sciences (MPS)", "MID-SCALE INSTRUMENTATION" ], "program_reference_codes": [], "program_officials": [ { "id": 18726, "first_name": "Nigel", "last_name": "Sharp", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2008-10-01", "end_date": "2014-09-30", "award_amount": 9000000, "principal_investigator": { "id": 18730, "first_name": "Daniel", "last_name": "Eisenstein", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 1397, "ror": "", "name": "Astrophysical Research Consortium", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 18727, "first_name": "David J", "last_name": "Schlegel", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 18728, "first_name": "Constance M", "last_name": "Rockosi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 18729, "first_name": "Steven R", "last_name": "Majewski", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1397, "ror": "", "name": "Astrophysical Research Consortium", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "This project builds on the legacy of the two previous Sloan Digital Sky Survey programs (SDSS and SDSS-II). This project consists of four surveys. \n\nThe NSF funding is primarily for the Baryon Oscillation Spectroscopic Survey (BOSS). This survey will measure redshifts of 1.5 million luminous red galaxies and Lyman-alpha absorption towards 160,000 high redshift quasars. These measurements will permit the absolute cosmic distance scale to be determined to a higher precision (1.0-1.5%) than previously achieved and will provide constraints on the equation of state of dark energy. Some of the NSF funds will also be used to support the Apache Point Observatory Galactic Evolution Experiment (APOGEE). This survey will use high-resolution and high signal-to-noise infrared spectroscopy to penetrate the dust that obscures the inner Galaxy from our view, measuring radial velocities, spectral types, and detailed elemental abundances of 100,000 red giant stars to an H magnitude limit of approximately 13.5 across the full range of the Galactic bulge, bar, and disk.\n\nThe first of the non-NSF funded surveys is SEGUE-2 which will measure radial velocities, spectral types, and elemental abundances of 350,000 stars in numerous target categories to a g magnitude limit of approximately 19, which will probe the kinematics and chemical evolution of the outer Milky Way. The final survey, also non-NSF funded, is the Multi-Object APO Radial Velocity Exoplanet Large-area Survey (MARVELS). This will monitor the radial velocities of 11,000 bright stars, with the precision and cadence needed to detect gas giant planets with orbital periods ranging from several hours to two years. These observations will provide a critical statistical data set for testing theories of the formation and dynamical evolution of planetary systems.\n\nThese surveys will produce large, well calibrated, easily accessible public databases supporting astronomical research and educational activities at many levels. The project also includes an active program of education and outreach promoting the data and tools to K-12 and university educators and to the broader public.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "6717", "attributes": { "award_id": "2UL1TR001855-06A1", "title": "Southern California Clinical and Translational Science Institute", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 22468, "first_name": "Deborah", "last_name": "Philp", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2016-07-01", "end_date": "2027-03-31", "award_amount": 9009695, "principal_investigator": { "id": 22469, "first_name": "Thomas A", "last_name": "Buchanan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 152, "ror": "https://ror.org/03taz7m60", "name": "University of Southern California", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22470, "first_name": "Michele D.", "last_name": "Kipke", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 152, "ror": "https://ror.org/03taz7m60", "name": "University of Southern California", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Contact PD/PI: Buchanan, Thomas A OVERALL COMPONENT Project Summary/Abstract The Southern California Clinical and Translational Science Institute (SC CTSI) is submitting this revision for a third cycle of Clinical and Translational Science Award (CTSA) funding at a time of dramatic growth and opportunity at our hub. The SC CTSI encompasses the University of Southern California (USC) and Children's Hospital of Los Angeles (CHLA), in close partnership with the Los Angeles County Department of Health Services. Our vision is to be a leader in clinical and translational research to benefit diverse communities and special populations. Our approach builds on past success, acknowledging the changing landscape of clinical and translational research (CTR), the priorities of the CTSA program, and the evolving needs of our researchers, trainees, patients and communities. Our scope leverages strengths in clinical, health system, and community research, education and training, within two overarching themes: diversity and impact. Diversity is reflected in the communities, health systems, and scientific disciplines we engage to improve health care and outcomes. Impact encompasses academic productivity as well as benefit to our workforce, health systems, patients, and communities. To pursue our vision in the context of our scope and themes, we propose six specific aims: (1) Workforce Development: Train a highly skilled workforce with the knowledge, skills, and attitudes to conduct rigorous and reproducible research focused on the evolving health needs of diverse communities. (2) Collaboration and Engagement: Create a culture in which team-based research, engaging all stakeholders and following sound principles of team science, is the standard approach to addressing complex challenges in health and research. (3) Integration: Engage our diverse communities to establish clinical research priorities; identify barriers to research; and develop, demonstrate and disseminate innovative approaches to assure fully partnered clinical research across communities and the lifespan. (4) Methods and Process: Apply principles of quality and process improvement to clinical and translational research to develop and share novel approaches to enhance efficiency, quality and impact. (5) Informatics: Provide an agile information ecosystem that encompasses research, clinical care, communities and their environment, providing a holistic view of health and disease and serving as the engine for discovery, innovation and insight. (6) CTSA Hub: Participate in CTSA network activities, conduct multi-site studies, adopt successful models from peers, and develop, demonstrate and disseminate innovative approaches. Achieving these aims will advance the discipline of CTR directed at improving health in diverse and underserved communities. Glossary ACT – CTSA Program Accrual to Clinical Trials Network IRB – Institutional Review Board BERD – Biostatistics, Epidemiology, Research Design core group ISI – USC Information Sciences Institute CD2H – CTSA Program National Center for Data to Health IT – Information Technology CE – Community Engagement core group KSOM – Keck School of Medicine of USC CEREC – CTSA External Reviewer Exchange Consortium LA – Los Angeles CHDP – Community Health Demonstration Projects LAC DHS – LA County Department of Health Services CHLA – Children's Hospital Los Angeles LGBTQ+ – Lesbian, Gay, Bisexual, Transgender, Questioning CLIC – CTSA Center for Leading Innovation and Collaboration MRC – Mentor Resource Center CLS – Community Listening Session N3C – National COVID Cohort Collaborative CRI – Clinical Research Informatics core group NGHP – Nickerson Gardens Housing Project CSU – Colorado State University NIH – National Institutes of Health CSULA – California State University Los Angeles NLP – Natural Language Processing CTR – Clinical and Translational Research OC/OH-LA – Our Community/Our Health Los Angeles CTTI – Clinical Trials Transformation Initiative PBRN – Practice-Based Research Network DIAMOND – Development, Implementation, and Assessment of Novel Training in Domain-based Competencies Portal QbD – Quality by Design EAC – External Advisory Committee SC CTSI – Southern California Clinical and Translational Science Institute EDWAP – Enterprise Data Warehouse and Analytics Platform SEDoH – Social and Environmental Determinants of Health EHR – Electronic Health Record SNA – Social Network Analysis ERC – Education Resource Center SSI – USC Spatial Sciences Institute FHIR – Fast Healthcare Interoperability Resources STELLAR – Self Career Training Education Lifelong Learning Advancement Resource, a collaboration with Georgia CTSA HACLA – Housing Authority of the City of Los Angeles TBV – Team Building Voucher HDS – Healthcare Delivery Science TIN – Trial Innovation Network HHS – Hollywood, Health & Society TS – Team Science I2b2 – Informatics for Integrating Biology & the Bedside UCLA – University of California Los Angeles ICD – Institutional Career Development URM – Under-Represented in Medicine IIT – Investigator-Initiated Trial USC – University of Southern California IOB – Internal Oversight Board WD – Workforce Development core group Project Summary/Abstract Page 207 Contact PD/PI: Buchanan, Thomas A UL1", "keywords": [ "Address", "Adopted", "Advisory Committees", "African American", "Area", "Artificial Intelligence", "Asian Americans", "Attitude", "Biology", "Biometry", "California", "Child Health Services", "Cities", "Clinical", "Clinical Research", "Clinical Sciences", "Clinical Trials", "Clinical Trials Network", "Clinical and Translational Science Awards", "Collaborations", "Colorado", "Communities", "Community Health", "Community Health Aides", "Community Health Systems", "Competence", "Complement", "Complex", "County", "Data", "Data Analytics", "Development", "Development Plans", "Discipline", "Disease", "Ecosystem", "Electronic Health Record", "Environment", "Fast Healthcare Interoperability Resources", "Fostering", "Funding", "Gardenal", "Glossary", "Goals", "Growth", "Health", "Health Services", "Health system", "Housing", "Improve Access", "Individual", "Informatics", "Information Sciences", "Information Technology", "Institutes", "Institution", "Institutional Review Boards", "Instruction", "Knowledge", "Latino", "Leadership", "Lesbian Gay Bisexual Transgender", "Lesbian Gay Bisexual Transgender Queer", "Longevity", "Los Angeles", "Machine Learning", "Medicine", "Mentors", "Methods", "Mission", "Modeling", "Natural Language Processing", "Pathway Analysis", "Patients", "Pediatric Hospitals", "Peer Review", "Plant Roots", "Population", "Population Heterogeneity", "Population Research", "Process", "Productivity", "Program Sustainability", "Reproducibility", "Request for Applications", "Research", "Research Design", "Research Institute", "Research Personnel", "Research Priority", "Research Training", "Resources", "Role", "Science", "Services", "Site", "Social Network", "Social Sciences", "Societies", "Special Population", "Subgroup", "Talents", "Television", "Time", "Training", "Training and Education", "Translating", "Translational Research", "Translations", "United States National Institutes of Health", "Universities", "Vision", "Work", "Workforce Development", "authority", "base", "care outcomes", "career", "career development", "clinical care", "cohort", "community based participatory research", "community engaged research", "community engagement", "coronavirus disease", "data hub", "data infrastructure", "data warehouse", "design", "education resources", "epidemiology study", "experience", "health care delivery", "health data", "health organization", "improved", "innova" ], "approved": true } }, { "type": "Grant", "id": "14572", "attributes": { "award_id": "2037026", "title": "FMRG: Manufacturing ADvanced Electronics through Printing Using Bio-based and Locally Identifiable Compounds (MADE-PUBLIC)", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Engineering (ENG)", "SSA-Special Studies & Analysis" ], "program_reference_codes": [], "program_officials": [ { "id": 8531, "first_name": "Siddiq", "last_name": "Qidwai", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-01-01", "end_date": null, "award_amount": 9150001, "principal_investigator": { "id": 25288, "first_name": "Junhong", "last_name": "Chen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 5112, "first_name": "Mark C", "last_name": "Hersam", "orcid": "https://orcid.org/0000-0003-4120-1426", "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": "['http://www.hersam-group.northwestern.edu/']", "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 317, "ror": "https://ror.org/000e0be47", "name": "Northwestern University", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, { "id": 31223, "first_name": "Stuart J", "last_name": "Rowan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 31224, "first_name": "Santanu", "last_name": "Chaudhuri", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 31225, "first_name": "Elizabeth", "last_name": "Ainsworth", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "This Future EcoManufacturing research grant will enable a future intelligent, scalable, and democratized manufacturing paradigm that allows for distributed printing of low-cost, biodegradable, and recyclable electronic devices using locally identifiable resources, such as bio-based materials derived from plants. These electronic devices are critical components in the rapidly evolving Internet of Things (IoT). The distributed manufacturing can lower overall device costs (by saving transportation costs) and make the supply chain more resilient during disruptions (e.g., during a pandemic). This project will demonstrate as a prototype the distributed printing of a lithium-ion battery (LIB) - powered chemical sensors using plant-derived inks. The printed devices will be used for monitoring growth conditions of hydronic plants that are used to derive the inks. The same platform can be used to print many other sophisticated, biodegradable/recyclable electronic devices using bio-based materials through customization and active learning. Through partnership with community colleges, Manufacturing USA Institutes, and manufacturing incubators, the project aims to educate, train, engage, and excite diverse student audiences and the public on the future sustainable manufacturing through several new, tailored initiatives, such as a cross-institutional certificate program, printable electronics hackathon and DIY initiative, and citizen science competition. <br/><br/>The goal of the project is to enable a manufacturing supply chain from precision agriculture/hydroponics to advanced biodegradable and recyclable electronics. The project will lead to major science advances in three domains: precision growth of plants, manufacturing of tailored bio-based inks, and sustainable production of printable electronics. As a convergent research program, the project will further lead to value-added transferrable and scalable scientific advancements, including novel artificial intelligence/machine learning (AI/ML) algorithms for manufacturing, a framework for designing sustainable and systematically optimized manufacturing processes, and techniques for incorporating heterogeneous data into manufacturing data systems while automatically refining the models. Learned models will correlate plant phenotypes and growth conditions with cellulose and lignin extraction, connect ink formulation with desired ink properties, and associate printing parameters with electronic device performance and quality. The project will lead to an open-source biomaterials-based electronics manufacturing data infrastructure (BEMDI) that fosters innovation through building a community of innovators, educators, and industry partners interested in manufacturing bio-based printable electronics. This Future Manufacturing research is supported by the Divisions of Civil, Mechanical and Manufacturing Innovation (CMMI), Biological Sciences (BIO), Emerging Frontiers and Multidisciplinary Activities (EFMA), Materials Research (DMR), Electrical Communications and Cyber Systems (ECCS), Engineering Education and Centers (EEC), and Mathematical Sciences (DMS).<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9101", "attributes": { "award_id": "3OT2HL156812-01S5", "title": "ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)", "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 7612, "first_name": "ANTONELLO", "last_name": "PUNTURIERI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-06-15", "end_date": "2022-05-31", "award_amount": 9156816, "principal_investigator": { "id": 7614, "first_name": "Sonia M", "last_name": "Thomas", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 809, "ror": "", "name": "RESEARCH TRIANGLE INSTITUTE", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 809, "ror": "", "name": "RESEARCH TRIANGLE INSTITUTE", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "RTI International is pleased to provide this application as requested by the Research Opportunities Announcement OTA-20-011 ACTIV Integration of Host-targeting Therapies for COVID-19 for the role of Administrative Coordinating Center (ACC). The title of our application is ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center. The Integration of Host-targeting Therapies for COVID-19 Program aims to identify COVID-19 interventions relevant to heart, lung, blood, and cardiovascular outcomes that contribute to the scientific knowledge base are likely to inform clinical practice. This Program will rapidly and efficiently conduct adaptive platform trials via a coordinated effort of Data Coordinating Centers and clinical sites from existing Clinical Study Networks. The ACC is a critical component of the Program. We will coordinate with NHLBI to ensure collaboration among networks including the use of standardized approaches in clinical trial design and conduct, data collection and validation, and statistical analysis such that studies are launched, implemented and analyzed swiftly; and study findings are scientifically sound and meet regulatory needs for medical therapy development. As the ACC, we will also serve the vital role of facilitating communication and information sharing among all relevant stake holders and helping NHLBI in tracking study-specific and Program-wide milestones. Sonia Thomas, DrPH, will lead the ACC as Principal Investigator. She is an experienced CC PI and statistician with 25 years of experience in the design, implementation, and analysis of multicenter NIH- and industry-sponsored Phase 2-4 clinical trials of drugs, biologics, devices, surgical and behavioral interventions in more than a dozen therapeutic indications. Dr. Thomas will be supported by Tracy Nolen, DrPH as Alternate PI, an experienced Consortium and CC PI and clinical trial statistician, and subject matter experts Steve Nissen, MD, Cleveland Clinical Chief Academic Officer, Heart and Vascular Institute, Shannon Carson, MD, Univ. of North Carolina Chief of Pulmonary and Critical Care Medicine, and Anastasia Ivanova, PhD, Univ. of North Carolina Professor of Biostatistics Under Dr Thomas’s direction, our team will lead, support, and collaborate with Program Networks through organization into 6 ACC Cores: Program Operations, Scientific Leadership and Prioritization, Informatics, Data Standards, Study Design, Implementation, & Analysis, and Regulatory and QA. We have identified milestones for the essential activities of the ACC within each of these 6 Cores with a detailed focus on the activities in the first 6 months as activities completed during this time are most important for ensuring the coordinated, expedited and efficient launch of this Program. Dr. Thomas, our subject matter experts, senior statistical scientists, and many of the core leads have substantial experience with NHLBI and thus understand the needs and priorities of the Institute and will use this knowledge to better collaborate with NHLBI and further speed up the launch of this Program. We are willing to collaborate with all involved entities as part of the overarching trans-NIH ACTIV Program as it evolves. We recognize and anticipate that swift adaptation will be required to rapidly respond to the urgent clinical research needs to address the COVID-19 pandemic. RTI is uniquely and substantially qualified for the ACC. We will use our team’s broad experience from many complex coordinating center projects to anticipate the needs for this Program and “hit the ground running”. Proven informatics technology in use by existing NIH programs will be swiftly modified by our analysts for speedy deployment of communications platforms. Our organizational size and flexibility will allow us to ramp up quickly and modify personnel resources flexibly. Lastly, RTI has a proven track record of successful collaborations with other coordinating centers on complex programs, yet as we are not directly involved with any Networks for consideration to be NHLBI COVID-19 trials sites, we provide independence and objectivity to the Program.", "keywords": [ "Address", "Adoption", "Area", "Behavior Therapy", "Biological", "Biometry", "Blood", "COVID-19", "COVID-19 intervention", "COVID-19 pandemic", "COVID-19 treatment", "Cardiovascular system", "Clinic", "Clinical", "Clinical Research", "Clinical Trials", "Clinical Trials Design", "Clinical Trials Network", "Collaborations", "Communication", "Complex", "Consensus", "Critical Care", "Data Collection", "Data Coordinating Center", "Development", "Devices", "Doctor of Philosophy", "Documentation", "Effectiveness", "Ensure", "Funding", "Goals", "Heart", "Human Resources", "Image", "Industry", "Informatics", "Information Dissemination", "Infrastructure", "Institutes", "International", "Knowledge", "Lead", "Leadership", "Lung", "Medical", "Medicine", "National Heart Lung and Blood Institute", "North Carolina", "Online Systems", "Operative Surgical Procedures", "Outcome", "Pharmaceutical Preparations", "Phase", "Principal Investigator", "Process", "Ramp", "Reporting", "Research", "Research Design", "Resources", "Role", "Running", "Scientist", "Site", "Speed", "Standardization", "Statistical Data Interpretation", "Technology", "Therapeutic", "Time", "United States National Institutes of Health", "Universities", "Validation", "clinical practice", "clinical research site", "data harmonization", "data quality", "data standards", "design", "experience", "flexibility", "informatics tool", "insight", "knowledge base", "operation", "professor", "programs", "protocol development", "sound", "targeted treatment", "therapy development" ], "approved": true } }, { "type": "Grant", "id": "7300", "attributes": { "award_id": "3UM1AI148574-01S1", "title": "Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 7539, "first_name": "Marina", "last_name": "Lee", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-08-21", "end_date": "2021-09-09", "award_amount": 9214781, "principal_investigator": { "id": 23088, "first_name": "Mark Joseph", "last_name": "Mulligan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 832, "ror": "", "name": "NEW YORK UNIVERSITY SCHOOL OF MEDICINE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 832, "ror": "", "name": "NEW YORK UNIVERSITY SCHOOL OF MEDICINE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "This supplement proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) research to be carried out at the NYU VTEU. We will participate in the implementation of a COVID-19 vaccine efficacy trial “A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, A Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19.” In addition to the above, and as a supplement request to further address the mission of the CoVPN, we are requesting funds for other CoVPN studies “and other COVID-related research”. We plan to conduct an additional study within the CoVPN – Monoclonal Antibody (mAb) Studies: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS- CoV-2 Monoclonal Antibodies in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2. With the global COVID-19 pandemic, we recognize a significant need for vaccines that modify COVID-19 in SARS-CoV-2 infected individuals. The vaccine trial we will conduct is a phase 3, placebo-controlled, double- blinded study will test the efficacy of AZD1222, a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein, to modify COVID-19 disease in adults 18 year of age and older. Participants will be recruited from up to 100 clinical trial sites across the US, using data analytics to target high risk individuals with a diverse racial and ethnic profile. The MAB study we will conduct is a pivotal phase 3 randomized, double-blind, placebo-controlled study in adults with household contact exposure to individuals with SARS-CoV-2 infection in geographic areas with an active COVID-19 outbreak. An ideal agent for prophylaxis should be fast acting and highly effective and should protect against multiple viral variants. A monoclonal antibody (mAb) combination therapy, with two different monoclonal antibodies that bind distinct regions of the portion of the SARS-CoV-2 spike (S) protein that bind to and facilitate entry into host cells, has been developed in order to achieve these goals. A mAb combination against SARS-CoV-2 for post-exposure prophylaxis that can either prevent the development of disease or reduce viral acquisition or shedding could be key to reducing transmission of the virus and limiting symptoms and adverse outcomes following infection. We also request site preparedness funds, and fund for Dr Mulligan’s role as national PI of an additional MAB study (Lilly MAB in nursing home residents and staff, for COVID-19 prevention).", "keywords": [ "18 year old", "2019-nCoV", "Address", "Adenoviruses", "Adult", "Age-Years", "Antibody Response", "Antigens", "Binding", "Binding Proteins", "Biological Assay", "Biometry", "COVID-19", "COVID-19 pandemic", "COVID-19 vaccine", "Cells", "Cellular Assay", "Clinical", "Clinical Trials", "Cohort Studies", "Combined Modality Therapy", "Communicable Diseases", "Data Analytics", "Development", "Disease", "Disease Outbreaks", "Dose", "Double-Blind Method", "Emergency department visit", "Evaluation", "Exposure to", "Eye", "Funding", "Geographic Locations", "Goals", "HIV vaccine", "Health", "Household", "Immune", "Immune response", "Immunity", "Immunology", "Individual", "Infection", "Infection Control", "Knowledge", "Laboratories", "Lead", "Leadership", "Malaria", "Mediating", "Membrane Glycoproteins", "Mission", "Monoclonal Antibodies", "Morbidity - disease rate", "Multicenter Studies", "New York", "Nursing Homes", "Pan Genus", "Participant", "Persons", "Phase", "Placebos", "Population", "Preparation", "Prevention", "Prophylactic treatment", "Protocols documentation", "Quality Control", "Randomized", "Randomized Clinical Trials", "Readiness", "Recombinants", "Research", "Research Methodology", "Risk", "Role", "Safety", "Sampling", "Serological", "Serum", "Severities", "Site", "Symptoms", "System", "Typhoid Fever", "Universities", "Vaccines", "Validation", "Variant", "Viral", "adverse outcome", "clinical trial analysis", "coronavirus disease", "design", "efficacy study", "efficacy testing", "efficacy trial", "high risk", "immune function", "immunogenicity", "mortality", "neutralizing antibody", "placebo controlled study", "prevent", "programs", "quality assurance", "racial and ethnic", "racial diversity", "recruit", "response", "vaccine trial", "vector vaccine", "viral transmission" ], "approved": true } }, { "type": "Grant", "id": "15768", "attributes": { "award_id": "75N92023D00011-0-759202500001-1", "title": "COPD GENE - GENETIC EPIDEMIOLOGY OF COPD - TASK AREA A: YEAR 3 - AUGUST 10, 2025 - AUGUST 9, 2026", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2025-08-10", "end_date": "2026-08-09", "award_amount": 9292344, "principal_investigator": { "id": 32839, "first_name": "LEE S", "last_name": "NEWMAN", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2636, "ror": "", "name": "NATIONAL JEWISH HEALTH", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "Genetic Epidemiology of COPD (COPDGene) is a multi-site longitudinal cohort study of current and former smokers to better understand risk factors, natural history, and genetic contributions of chronic obstructive pulmonary disease (COPD) as well as other smoking-related diseases. The purpose of this acquisition is to fund a 15-year follow-up in-person clinical visit (Visit 4) of this cohort, to be re-enrolled from approximately 19 active Clinical Study Centers. A Visit 4 of COPDGene subjects is needed to identify clinical, physiological, imaging, and Omics determinants of COPD and other disease progression in elderly subjects, to assess the impact of COVID-19 on COPD and other disease progression, and to discover determinants of severe COPD development in subjects with preserved ratio, impaired spirometry (PRISm). The acquisition will also support the maintenance of previously collected data and biospecimens, regulatory oversight of the study, and analysis of study data and study biospecimens. The goal of COPDGene is to use extensive longitudinal imaging, physiology, and Omics molecular data in combination with genetics in the COPDGene cohort to identify high-risk subgroups with distinct diagnostic, prognostic, and therapeutic implications. COPDGene has been funded for 15 years through grants and cooperative agreements awarded by NHLBI to National Jewish Health and Brigham and Women’s Hospital. Grant applications for the three Phases of COPDGene [Phase 1: baseline visit (“Visit 1”); Phase 2: five year follow-up (“Visit 2”); Phase 3: ten year follow-up (“Visit 3”)] were all submitted to the parent NIH R01 Funding Opportunity Announcement. Study investigators originally recruited 10,198 current or former smokers in Phase 1. Including nonsmoking controls from both Phase 1 and Phase 2, COPDGene has recruited a total 10,718 subjects all of whom have been extensively phenotyped clinically and radiologically. Additional data collected on these participants include whole genome sequencing as well as RNA sequencing, proteomics, metabolomics, and DNA methylation data from collected blood samples. Investigators have published more than 450 publications, the vast majority of which were peer-reviewed, using COPDGene data. COPDGene also serves as a parent study for many ancillary studies, using public or private funding, a subset of which have collected additional data on all or a subset of participants. COPDGene is overseen by an NHLBI-convened Observational Study Monitoring Board (OSMB). The Visit 4 (15-year follow-up) evaluations will include, where possible, lung function tests (spirometry), questionnaires (including COVID-19 assessment), chest computerized tomography (CT), other functional assessments (e.g., six minute walk distance), and collection and storage of biospecimens from 3,500 of the original 10,718 COPDGene subjects. In addition, this acquisition will support continuation of semi-annual long-term follow-up of the COPDGene cohort and other contact with the cohort as needed, oversight of clinical sites and human subjects protection, maintenance of the database and biobank, continued coordination with NIH and NHLBI data resources, activities relevant to the data management and sharing plan, analysis of data, travel to meetings, and publication costs.", "keywords": [ "Address", "Adverse event", "Ancillary Study", "Annual Reports", "Applications Grants", "Archives", "Area", "Award", "Bioinformatics", "Biological Markers", "Biological Specimen Banks", "Blood specimen", "Bronchodilator Agents", "COVID-19", "COVID-19 impact", "Cause of Death", "Certification", "Cessation of life", "Characteristics", "Chest", "Chronic Obstructive Pulmonary Disease", "Clinical", "Clinical Data", "Clinical Research", "Clinical/Radiologic", "Collaborations", "Collection", "Communication", "Communities", "Compensation", "Computer Security", "Contractor", "Contracts", "DNA Methylation", "Data", "Data Analyses", "Data Coordinating Center", "Data Science", "Data Security", "Data Set", "Databases", "Development", "Diagnostic", "Diffusion", "Disease Progression", "Documentation", "Educational workshop", "Elderly", "Electronics", "Enrollment", "Ensure", "Epidemiology", "Evaluation", "Event", "Funding", "Funding Opportunities", "Future", "Genes", "Genetic", "Genomics", "Goals", "Grant", "Health", "Hospitals", "Image", "Impairment", "Information Systems", "Institutional Review Boards", "International", "Internet", "Jews", "Journals", "Laboratories", "Link", "Long-term Follow-up", "Longitudinal cohort study", "Maintenance", "Manuscripts", "Measures", "Medical History", "Metadata", "Methods", "Molecular", "Monitor", "Names", "National Heart Lung and Blood Institute", "Natural History", "Observational Study", "Outcome", "Oxygen", "Parents", "Participant", "Peer Review", "Persons", "Phase", "Physical Performance", "Physiological", "Physiology", "Policies", "Privatization", "Procedures", "Proteomics", "Protocols documentation", "PubMed", "Publications", "Publishing", "Pulmonary Emphysema", "Pulmonary function tests", "Quality Control", "Quality of life", "Questionnaires", "Recommendation", "Reporting", "Research", "Research Personnel", "Resolution", "Resources", "Risk Factors", "SARS-CoV-2 infection", "Scanning", "Schedule", "Scientist", "Site", "Specific qualifier value", "Spirometry", "Standardization", "Subgroup", "Support Contracts", "System", "Teleconferences", "Telephone", "Testing", "Therapeutic", "Time", "Tobacco use", "Training", "Trans-Omics for Precision Medicine", "Travel", "U-Series Cooperative Agreements", "United States National Institutes of Health", "Update", "Vaccination", "Visit", "Walking", "Woman", "Work", "X-Ray Computed Tomography", "adjudication", "biobank", "catalyst", "clinical ce" ], "approved": true } }, { "type": "Grant", "id": "15497", "attributes": { "award_id": "75N92023D00011-0-759202400001-1", "title": "GENETIC EPIDEMIOLOGY OF COPD (COPD GENE) 2024 - 2025 TASK ORDER FOR TASK AREA A: COLLECTION OF COPDGENE STUDY DATA AND BIOSPECIMENS AND OVERSIGHT OF THE COPDGENE STUDY.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-08-10", "end_date": "2025-08-09", "award_amount": 9298220, "principal_investigator": { "id": 32045, "first_name": "JAMES", "last_name": "CAPPO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1553, "ror": "https://ror.org/016z2bp30", "name": "National Jewish Health", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "Genetic Epidemiology of COPD (COPDGene) is a multi-site longitudinal cohort study of current and former smokers to better understand risk factors, natural history, and genetic contributions of chronic obstructive pulmonary disease (COPD) as well as other smoking-related diseases. The purpose of this acquisition is to fund a 15-year follow-up in-person clinical visit (Visit 4) of this cohort, to be re-enrolled from approximately 19 active Clinical Study Centers. A Visit 4 of COPDGene subjects is needed to identify clinical, physiological, imaging, and Omics determinants of COPD and other disease progression in elderly subjects, to assess the impact of COVID-19 on COPD and other disease progression, and to discover determinants of severe COPD development in subjects with preserved ratio, impaired spirometry (PRISm). The acquisition will also support the maintenance of previously collected data and biospecimens, regulatory oversight of the study, and analysis of study data and study biospecimens. The goal of COPDGene is to use extensive longitudinal imaging, physiology, and Omics molecular data in combination with genetics in the COPDGene cohort to identify high-risk subgroups with distinct diagnostic, prognostic, and therapeutic implications. COPDGene has been funded for 15 years through grants and cooperative agreements awarded by NHLBI to National Jewish Health and Brigham and Women’s Hospital. Grant applications for the three Phases of COPDGene [Phase 1: baseline visit (“Visit 1”); Phase 2: five year follow-up (“Visit 2”); Phase 3: ten year follow-up (“Visit 3”)] were all submitted to the parent NIH R01 Funding Opportunity Announcement. Study investigators originally recruited 10,198 current or former smokers in Phase 1. Including nonsmoking controls from both Phase 1 and Phase 2, COPDGene has recruited a total 10,718 subjects all of whom have been extensively phenotyped clinically and radiologically. Additional data collected on these participants include whole genome sequencing as well as RNA sequencing, proteomics, metabolomics, and DNA methylation data from collected blood samples. Investigators have published more than 450 publications, the vast majority of which were peer-reviewed, using COPDGene data. COPDGene also serves as a parent study for many ancillary studies, using public or private funding, a subset of which have collected additional data on all or a subset of participants. COPDGene is overseen by an NHLBI-convened Observational Study Monitoring Board (OSMB). The Visit 4 (15-year follow-up) evaluations will include, where possible, lung function tests (spirometry), questionnaires (including COVID-19 assessment), chest computerized tomography (CT), other functional assessments (e.g., six minute walk distance), and collection and storage of biospecimens from 3,500 of the original 10,718 COPDGene subjects. In addition, this acquisition will support continuation of semi-annual long-term follow-up of the COPDGene cohort and other contact with the cohort as needed, oversight of clinical sites and human subjects protection, maintenance of the database and biobank, continued coordination with NIH and NHLBI data resources, activities relevant to the data management and sharing plan, analysis of data, travel to meetings, and publication costs.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9453", "attributes": { "award_id": "75N95020D00016-0-759502100001-1", "title": "NCATS SECURE SCIENTIFIC PLATFORMS ENVIRONMENT SUPPORT FOR THE N3C DATA ENCLAVE, POP 12/25/2020 - 9/27/2021", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-12-25", "end_date": "2021-09-27", "award_amount": 9554920, "principal_investigator": { "id": 25170, "first_name": "BRIAN", "last_name": "ZAVERTNICK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1737, "ror": "", "name": "PALANTIR TECHNOLOGIES, INC.", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1737, "ror": "", "name": "PALANTIR TECHNOLOGIES, INC.", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "The NCATS National COVID Cohort Collaborative (N3C) Data Enclave, a centralized and secure data platform featuring powerful analytics capabilities for online discovery, visualization and collaboration for researchers studying COVID-19. The data are robust in scale and scope and are transformed into a harmonized data set to help scientists study COVID 19, including potential risk factors, protective factors and long-term health consequences. The N3C Data Enclave is anticipated to be one of the largest collections of data on COVID-19 patients in the United States. Data analysis within the enclave is supported by both R and Python, the most widely used open-source platforms for statistical analysis and data science. Researchers requesting access to, or working within, the enclave are encouraged to assemble collaborative teams with diverse expertise in such areas as clinical research, statistical analysis and informatics to make the best use of the N3C Data Enclave. A core tenet of the enclave is that it is both accessible and secure, allowing researchers to pursue research in a safe environment conducive to collaborative discovery while also allowing for the deployment of a wide variety of open source tools and components.", "keywords": [ "Area", "COVID-19", "COVID-19 patient", "Clinical Research", "Collaborations", "Data", "Data Analyses", "Data Collection", "Data Science", "Data Set", "Environment", "Health", "Informatics", "Pythons", "Research", "Research Personnel", "Risk Factors", "Scientist", "Secure", "Statistical Data Interpretation", "United States", "Visualization", "cohort", "coronavirus disease", "data enclave", "data harmonization", "open source", "open source tool", "protective factors" ], "approved": true } }, { "type": "Grant", "id": "7572", "attributes": { "award_id": "3UM1AI148573-01S1", "title": "University of Washington Vaccine and Treatment Evaluation Unit", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 7539, "first_name": "Marina", "last_name": "Lee", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-03-12", "end_date": "2022-11-30", "award_amount": 9616028, "principal_investigator": { "id": 11527, "first_name": "Helen Ying-hui", "last_name": "Chu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23371, "first_name": "Anna", "last_name": "Wald", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "The proposed University of Washington (UW) Vaccine and Treatment Evaluation Unit (VTEU) will be led by highly experienced investigators in domestic and international clinical trials, and supported by a Steering Committee that includes leading experts in the areas of focus of this application, including respiratory infections, sexually transmitted infections, malaria challenge studies, enteric infections and other neglected tropical diseases. The co-Principal Investigators have conducted >30 clinical trials, most under IND; these include trials sponsored by NIAID, including VTEU contracts, HPTN and STI CTG, industry sponsors, and investigator-held IND. The proposed VTEU Research Clinic at Harborview Medical Center has been conducting clinical trials for several decades, and the recruitment, enrollment, and retention practices and policies have been well established. Our strong record in obtaining research funding has resulted in the UW School of Medicine providing ample space that has been specifically designed to accommodate clinical trials conducted in the area of Infectious Diseases. The UW VTEU will leverage the extraordinary breadth and depth of expertise, facilities, resources, populations, and geographic reach of the UW and our collaborating institutions. Locally, these include Seattle Children’s and the Fred Hutchinson Cancer Research Center, in addition to several campus locations for UW Medicine. Internationally, the investigators included in the UW VTEU also lead well-established and experienced research sites with outstanding infrastructure in Kenya (UW- Kenya and the Kenya Medical Research Institute), South Africa (University of Witwatersrand), and Peru (Asociación Civil Selva Amazónica). Both domestic and international investigators have vast experience in the conduct of clinical trials of vaccines and other therapeutics under IND, with many sponsored by NIAID. This consortium has demonstrated capacity to recruit and retain the populations targeted by the VTEUs, including healthy volunteers, pregnant women, children, persons with or at risk for sexually transmitted infections, and participants in human challenge studies. The Specific Aims of the UW VTEU are: 1. Recruit a wide range of participants in clinical trials approved by the Leadership Group; 2. Implement clinical trials in compliance with Good Clinical Practice Guidelines and other regulatory guidance; 3. Ensure participant safety and monitor trials for adverse events; 4. Support the Leadership Group in the development of clinical protocols, providing unique clinical and research laboratory capabilities, performing data analysis, and reporting the results of clinical trials; 5. Provide outstanding training opportunities and mentorship to early stage investigators who desire to gain experience in conducting clinical trials.", "keywords": [ "Address", "Adult", "Adverse event", "Africa South of the Sahara", "Area", "Biological Assay", "Cellular Immunology", "Child", "Childhood", "Clinic", "Clinical Investigator", "Clinical Practice Guideline", "Clinical Protocols", "Clinical Research", "Clinical Trials", "Committee Members", "Communicable Diseases", "Conduct Clinical Trials", "Contracts", "Country", "Cytomegalovirus", "Data Analyses", "Emerging Communicable Diseases", "Enrollment", "Ensure", "Evaluation", "Fred Hutchinson Cancer Research Center", "Funding", "Geography", "Good Clinical Practice", "HIV Vaccine Trials Network", "Hepatitis", "Human", "Individual", "Industry", "Influenza", "Influenza A Virus H1N1 Subtype", "Influenza A virus", "Infrastructure", "Institution", "International", "Kenya", "Knowledge", "Laboratories", "Laboratory Research", "Lead", "Leadership", "Location", "Malaria", "Medical Research", "Medical center", "Medicine", "Mentorship", "Mission", "Molecular Virology", "Monitor", "National Institute of Allergy and Infectious Disease", "Participant", "Peripheral Blood Mononuclear Cell", "Persons", "Peru", "Pharmaceutical Preparations", "Phase", "Policies", "Population", "Pregnant Women", "Principal Investigator", "Reporting", "Research", "Research Institute", "Research Personnel", "Resources", "Respiratory Tract Infections", "Ribosomal RNA", "Risk", "Running", "Safety", "Sexually Transmitted Diseases", "Simplexvirus", "Site", "South Africa", "Target Populations", "Testing", "Therapeutic", "United States National Institutes of Health", "Universities", "Vaccine Clinical Trial", "Vaccines", "Washington", "Women&apos", "s Health", "Work", "ZIKA", "clinical development", "clinical research site", "cost", "design", "enteric infection", "experience", "global health", "healthy volunteer", "industry partner", "malaria infection", "medical schools", "neglected tropical diseases", "novel", "novel strategies", "novel therapeutics", "novel vaccines", "pandemic disease", "participant safety", "programs", "recruit", "skills", "training opportunity", "vaccine development", "vaccine trial" ], "approved": true } } ], "meta": { "pagination": { "page": 1392, "pages": 1405, "count": 14046 } } }